Investment Thesis
BioCorRx is in severe financial distress with negative stockholders' equity of -$13.5M, indicating the company is technically insolvent. Revenue has collapsed 92.8% year-over-year to just $948.4K while operating losses of -$4.3M persist, demonstrating a non-viable business model. With only $287.7K in cash, a current ratio of 0.10x, and negative operating cash flow of -$1.5M, the company faces imminent liquidity crisis and potential bankruptcy.
Strengths
- Gross margin of 67.9% indicates products/services retain pricing power when sold
- Zero long-term debt eliminates debt service obligations
- Specialty outpatient facilities sector has structural demand drivers
Risks
- Negative stockholders' equity of -$13.5M represents technical insolvency and shareholder value destruction
- Revenue decline of 92.8% YoY indicates loss of core business or market rejection
- Critical liquidity crisis: $287.7K cash against $20.3M liabilities with current ratio of 0.10x
- Negative operating cash flow of -$1.5M with minimal cash reserves means days to months of runway
- Operating losses of -$4.3M on $948.4K revenue indicates fundamentally broken unit economics
- No insider buying activity in last 90 days suggests management lacks confidence
Key Metrics to Watch
- Cash balance and runway to insolvency
- Revenue stabilization or further deterioration
- Operating cash flow trajectory and burn rate
- Debt covenant compliance and bankruptcy filing risk
Financial Metrics
Revenue
948.4K
Net Income
-4.0M
EPS (Diluted)
$-0.24
Free Cash Flow
-1.5M
Total Assets
7.5M
Cash
287.7K
Profitability Ratios
Gross Margin
67.9%
Operating Margin
-453.1%
Net Margin
-421.0%
ROE
N/A
ROA
-53.0%
FCF Margin
-153.0%
Balance Sheet & Liquidity
Current Ratio
0.10x
Quick Ratio
0.09x
Debt/Equity
N/A
Debt/Assets
269.4%
Interest Coverage
-27.93x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-21T01:48:11.449205 |
Data as of: 2025-09-30 |
Powered by Claude AI